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Background: Targeted treatment, matched according to specific clinical criteria e.g. hip muscle weakness, may
result in better outcomes for people with patellofemoral pain (PFP). However, to ensure the success of future trials,
a number of questions on the feasibility of a targeted treatment need clarification. The aim of the study was to
explore the feasibility of matched treatment (MT) compared to usual care (UC) management for a subgroup of
people with PFP determined to have hip weakness and to explore the mechanism of effect for hip strengthening.
Methods: In a pragmatic, randomised controlled feasibility study, 24 participants with PFP (58% female; mean age
29 years) were randomly allocated to receive either MT aimed specifically at hip strengthening, or UC over an
eight-week period. The primary outcomes were feasibility outcomes, which included rates of adherence, attrition,
eligibility, missing data and treatment efficacy. Secondary outcomes focused on the mechanistic outcomes of the
intervention, which included hip kinematics.
Results: Conversion to consent (100%), missing data (0%), attrition rate (8%) and adherence to both treatment and
appointments (>90%) were deemed successful endpoints. The analysis of treatment efficacy showed that the MT
group reported a greater improvement for the Global Rating of Change Scale (62% vs. 9%) and the Anterior Knee
Pain Scale (−5.23 vs. 1.18) but no between-group differences for either average or worst pain. Mechanistic
outcomes showed a greatest reduction in peak hip internal rotation angle for the MT group (13.1% vs. −2.7%).
Conclusion: This feasibility study indicates that a definitive randomised controlled trial investigating a targeted
treatment approach is achievable. Findings suggest the mechanism of effect of hip strengthening may be to
influence kinematic changes in hip function in the transverse plane.
Trial registration: This study was registered retrospectively. ISRCTN74560952. Registration date: 2017–02-06.
Keywords: Knee, Strength training, Therapeutic exercise, Patellofemoral pain, Hip strengtheningBackground
Patellofemoral pain (PFP) is widely considered an
enigma of musculoskeletal medicine [1]. It has been re-
ported to affect six to 7 % of the adolescent population
[2] and one in six adults who consult their GP with knee
pain will be diagnosed with PFP [3]. Of major concern is
that recent studies have shown that 40 to 62% [2, 4] of
individuals with PFP, at one-year follow-up, report* Correspondence: A.Redmond@leeds.ac.uk
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One solution for improving PFP therapy, proposed by
the international PFP community, is to establish sub-
groups of the wider PFP population, to allow targeted
treatment, matched according to specific subgroup char-
acteristics [5–7]. Currently, a multimodal treatment
approach (a combination of individual treatments) is
recommended as best practice [8]. However, it is likely
that people with PFP will benefit from being stratified
and matched to specific interventions [9]. Despite
successive international consensus papers since 2011
recommending subgrouping [5–7, 10], very little literaturele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Participant eligibility criteria
Inclusion criteria
• Aged 18–40 years
• Reported insidious (non-traumatic) onset of anterior or retropatellar
knee pain
• Pain on two or more of the following activities: prolonged sitting,
kneeling, squatting, running, patella palpation, hopping, stair
walking, stepping down or isometric quadriceps contraction
• Peak hip abduction torque values [33]: Females [18–29 years] ≤ 94.1 Nm;
Females [30–39 years] ≤ 75.8 Nm; Males [18–29 years] ≤ 144.1 Nm;
Males [30–39 years] ≤ 139 Nm
Exclusion criteria
• Presence of inflammatory arthritis; knee pain referred from the hip
or lumbar spine; any history of significant knee surgery; other causes
of knee pain such as, but not restricted to: meniscal pathologies,
quadriceps tendon injuries, patella tendinopathy, tibial tubercle
apophysitis; bursitis
• Received any treatment within the last 3 months including
physiotherapy, podiatry etc.
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number of studies [11–15] have targeted treatment based
on single clinical features, although no definitive studies
exist to support targeted interventions in PFP.
Reduced hip muscle strength is considered an associ-
ated feature of PFP [16]. A number of authors have re-
ported promising clinical outcomes after prescribing hip
strengthening exercises for people with PFP [17–21]. It
has been proposed that individuals with PFP present
with a propensity towards increased hip adduction and
internal rotation during dynamic movement [22]. This is
a significant predictor of pain in PFP [23], thought to be
linked to increasing patellofemoral joint contact stress
[24]. Subsequently, correcting this altered movement
pattern is often seen as a desired outcome in interven-
tional studies [25].
There are however, conflicting findings around the
mechanistic effect of hip strengthening in PFP [25].
Some studies have demonstrated a post-interventional
change in kinematics [17, 26], whilst others have re-
ported no change [27, 28]. The reason for these conflict-
ing findings is unclear, however, the previous studies
showing no kinematic change [27, 28] have included ath-
letic cohorts and with one of the cohorts [27] clearly
showing a higher than normal baseline strength. Selfe
et al. (2016) [29] recently classified people with PFP into
three subgroups: ‘strong’, ‘weak and tighter’ and ‘weak and
pronated foot’. Notably, 22% were classified into the
‘strong’ subgroup with higher knee extension and hip
abduction strength that may not gain from a treatment
approach based on strengthening. A strengthening inter-
vention would likely have the greatest effect on the kine-
matics of those with baseline weakness.
Large trials exploring a stratified approach for PFP are
required, however, to ensure the success and effective-
ness of such trials, a number of feasibility questions need
to be answered. The primary purpose of this study was
therefore to explore the feasibility of treatment matched
to the specific clinical criteria of a selected subgroup
compared to usual care (UC) management to inform a
future stratified approach to PFP treatment. The a priori
selection of a subgroup with a specific characteristic
such as hip abductor weakness also provides the oppor-
tunity, as a secondary aim, to explore the mechanism of
effect as this has also been recently advocated for trials
of physical interventions [30].
Methods
Study design
The study was a pragmatic, randomised controlled feasi-
bility study in which participants were selected from an
on-going longitudinal cohort study. Twenty-six partici-
pants were identified from larger group of 70 PFP cases
on the basis of having hip abductor weakness at clinicalexamination and were randomised into receiving either
a matched treatment (MT) or UC in a 1:1 ratio. Ethical
approval was obtained prior to commencement of the
study (14/NE/1131). All participants completed written
informed consent prior to entering the study. The study
has been reported in accordance with Consolidate
Standard of Reporting Trials (CONSORT) [31] and
Template for Intervention Description and Replication
guidelines. (TiDieR) [32].Participants
Participants were recruited between November 2014 to
April 2016 from a large musculoskeletal and rehabilita-
tion service via clinician referrals, their SystmOne
database (a local electronic healthcare database), posters
displayed in the local hospital and an university alumni
volunteers website. Eligibility criteria were assessed both
verbally and clinically to ensure that the inclusion cri-
teria were addressed fully (Table 1). The most symptom-
atic knee was designated the index limb. Participants
were stratified based on hip abductor strength measured
using a Biodex isokinetic system 4 (IRPS Mediquipe,
UK). Hip abductor weakness was based on thresholds
defined a priori from age and gender normative data
[33] (Table 1). The relevant normative mean minus one
standard deviation (−1 SD) was used as the threshold for
allocation to the “weak” stratum based on previous rec-
ommendations [34].Sample size
The study was designed to recruit 12 participants per group
based on previous guidance for feasibility studies of this de-
sign [35]. Participants were followed up to 8 weeks post-
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time to demonstrate an effect in PFP [20, 27, 36].
Randomisation
The random allocation sequence was made according to
the output from a random number generator and con-
cealed within pre-sealed, opaque envelopes [37]. All
allocation and randomisation was conducted by the lead
author (BD).
Blinding
The outcome assessor was unblinded, however, patient
reported outcome measures (PROMs) were completed
in a separate room with no input from the assessor. The
biomechanical outcomes were acquired in accordance to
a strict study protocol to minimise variation and bias
[38]. Furthermore, the biomechanical outputs are auto-
mated so the lack of blinding is less of an issue.
Interventions
Participants randomised to the MT group were asked to
attend six supervised sessions of approximately 30 min
in duration once per week for 6 weeks at a local hospital.
Each week they also performed two additional sessions
on non-consecutive days independently at home, with
the intervening days allowing adequate rest [39]. Consid-
eration was made to the recommended determinants of
resistance exercise [40] when developing the study inter-
vention. The sessions were face to face, 1:1 sessions pro-
vided by the lead author (BD) a senior musculoskeletal
physiotherapist with over 8 years of clinical experience.
During these sessions, participants were given education
and justification of the treatment followed by three exer-
cises aimed at targeting coronal, sagittal and transverse
strength of the hip using resistance bands. Each week at
least one of the exercises would change with the aim of
providing variation and minimising tedium [41]. The
supervision sessions served as a means of ensuring both
treatment fidelity and tailoring. Fidelity was ensured by
checking the exercise technique and making corrections
to performance prior to these being performed inde-
pendently at home. Subsequent visits ensured this
instruction had been correctly applied or not. Tailoring
the intervention based on progressive loading was in line
with current recommendations [25]. Participants were
issued yellow (least resistance), red or green (most resist-
ance) resistance tubing (66fit Ltd. ™) and were allowed to
take it home. To progress the load and resistance, a Borg
Rate of Perceived Exertion scale (RPE) [42] was used
based on the recommendations when using resistance
band [43]. A RPE of >6 was considered desirable [39]
and participants were monitored after a few repetitions
to ensure this was what was being achieved. As partici-
pants were stratified for strength, the interventionrequired participants to perform 10 repetitions within
three sets as recommended for strength training [39]. Par-
ticipants were advised to ensure the time under tension
was 8 s (3 s concentric, 2 s isometric hold and 3 s eccentric
contraction). Strengthening was performed on each leg
alternatively providing a standardised rest between sets.
Exercise diaries (see Additional file 1) were issued to par-
ticipants to provide a reminder of the exercises and to
allow a measure of adherence. Participants were asked to
document each time each exercise was performed on their
diary sheet and return these at each visit.
Participants randomised to the UC group continued
with the same management of their condition as they
were planning to receive prior to the commencement of
the study. This included planned physiotherapy, podiatry
or no intervention, depending upon participant prefer-
ence. The type of management and number of sessions
was recorded for the UC group at follow-up.
Outcomes
In response to lack of agreed guidelines for outcomes in
feasibility studies [44], the primary feasibility outcomes
were adapted from recommendations made by Bugge
et al. (2013) [45] and Shanyinde et al. (2011) [46].
Feasibility outcomes
Recruitment & eligibility Recruitment and eligibility
was assessed using the rate of eligibility (%), the conver-
sion of eligible to consent (%) and a breakdown of re-
cruitment sources.
Randomisation & blinding The success of randomisa-
tion was assessed based on any problems being
highlighted and whether the randomisation process
yielded broad equality in both groups based on the dif-
ference in baseline characteristics. Intervention blinding
is not possible for a physiotherapeutic intervention of
this nature [47] and thus this could not be measured.
Adherence & acceptability Adherence was assessed by
the adherence rate to treatment (%) using exercise diar-
ies and adherence to appointments (%) based on the
number of ‘unable to attends’ (UTAs). The acceptability
was assessed by the attrition rate (%).
Outcome measures The outcome data was assessed
based on the amount of missing data (%) found in each
case report form.
Resources & study management The study manage-
ment was assessed qualitatively in terms of the logistics of
running the study and the safety of all study components.
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the efficacy of the study in terms of improvements in
pain and disability at eight-week follow-up. The follow-
ing outcomes were selected based on current
IMMPACT guidelines [48]:
1. Pain was assessed using two numerical rating scales
(NRS) with a 11 point scale for: i) the average pain
in the knee over the last week ii) the worst pain in
the knee over the last week.
2. Function was assessed using the Anterior Knee Pain
scale (AKPS), a 13-item knee specific self-reported
questionnaire [49] in which 100 is the maximum
achievable score and lower scores indicate greater
pain and disability
3. Rating of change measured on a 11-point global
rating of change scale (GROC) anchored with
“very much worse” to “completely recovered” [50].
Responses were dichotomised with values greater
than 0 (“unchanged”) indicating an improvement.
Mechanistic outcomes
The secondary aim of the study explored the potential
mechanistic effects of hip strengthening on the selected
sample. A selection of biomechanical variables were se-
lected a priori to prevent subsequent data mining [51].
Three-dimensional kinematics were assessed during
stair descent using a VICON, motion capture system
(Vicon Nexus Version 1.6; Vicon Motion Systems,
Oxford Metrics, Oxford, Uk) at a sampling rate of
200 Hz. The stair set-up and procedure is shown Fig. 1.
Stair descent was selected as this is a known aggravating
factor for PFP [52], deemed challenging enough to ob-
serve a kinematic change [53] but achievable for bothFig. 1 Stairs and platform used in the study. Participants descended
the stairs at a self-selected speed. Each participant completed a
minimum five successful stair descents. The descent was deemed
successful when the index limb was placed on step two in the
absence of any stumbles or hesitation. The gait cycle of interest was
similar to that used in previous studies [66] between step two and
ground floor. The variables of interest were captured during stance
phase; between toe on and toe off on step twoactive and sedentary participants. Further procedural de-
tails are available in Additional file 2.
Data collected was analysed in Visual 3D (C-Motion,
Rockville, Maryland). The pre-selected kinematics of
most theoretical interest for explaining the proposed
mechanism of action of the MT intervention were i)
peak hip internal rotation angle (peak IR) of the thigh
with respect to the pelvis; ii) peak hip adduction angle
(peak ADD) of the thigh with respect to the pelvis; iii)
total coronal hip range of movement (coronal ROM); iv)
total transverse hip (ROM) (transverse ROM). These
were calculated using the an X-Y-Z Cardan rotation se-
quence [54]. A reduction in the magnitude of all the
kinematic variables measured post-intervention was con-
sidered a favourable outcome.
A Biodex isokinetic system 4 (IRPS Mediquipe, UK)
was used to assess muscle strength. Both limbs were
tested, with the index limb tested after a practice test
using the contralateral limb. Testing the index limb
second minimises any learning-effect variability [55]. To
ensure accuracy, the Biodex calibration verification pro-
cedure was conducted uniformly in accordance with the
system operation manual. Further procedural details are
available in Additional file 3. Data was collected by
Biodex Advantage Software (IRPS Mediquipe, UK). The
isokinetic strength measures of interest were i) peak hip
abduction torque based on the maximum hip abduction
torque across five repetitions; ii) Peak knee extension
torque based on the maximum knee extension torque
across five repetitions.
Statistical methods
Statistical analysis was undertaken using SPSS (version
21.0 (Armonk, NY: IBM Corp). As hypothesis testing is
not advised for this size and type of study design [44],
descriptive statistics along with point estimates, confi-
dence intervals and effect sizes were presented for all
PROMs and biomechanical outcomes. Within-group
changes for all kinematic variables were expressed as a
percentage change of the total ROM. Feasibility out-
comes were described using descriptive statistics. To de-
termine, where possible, a quantifiable measure of the
feasibility outcomes, predetermined thresholds were
used to indicate either success or strategies required
(Table 2). Where it was not possible to use quantitative
data to demonstrate success, outcomes were reported
narratively.
Results
Feasibility outcomes
Figure 2 shows that 14 participants were randomised to
MT and 12 participants to UC. Of the participants in the
UC group, 55% received formal physiotherapy treatment,
which may or may not have included a strengthening
Table 2 Thresholds for feasibility outcomes
Outcome Indicator Successful Unsuccessful - strategies required
Recruitment & eligibility Conversion to consent (%) > 90 < 90
Adherence & acceptability Adherence rate to treatment (%) > 90 < 90
Adherence to appointment (%) > 90 < 90
Attrition rate (%) < 10 > 10
Outcome measures Missing data (%) <5 >5
Treatment efficacy Average NRS MD > 1.5 [67] MD < 1.5
Worst NRS MD > 1.5 [67] MD < 1.5
AKPS MD > 8 [58] MD < 8
MD mean difference, NRS numerical rating scale
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continuing with their normal self-management.
Recruitment & eligibility Over 15 months, of the 70
who were screened, 26 were eligible based on hip weak-
ness, an eligibility rate of 37.1%. All 26 eligible partici-
pants consented to the study (100% conversion to
consent). Recruitment was predominantly from the Syst-
mOne database 54% (14/26). Direct clinician referrals
15% (4/26), posters 23% (6/26) and a university alumni
online advert 8% (2/26) accounted for the other sources
of recruitment.Fig. 2 Flow of participants through the studyRandomisation and blinding No practical problems
were highlighted in the randomisation procedure. The
randomisation yielded reasonable equality in terms of
demographics and baseline symptoms (see Table 3). The
only notable difference was the larger number of people
with bilateral knee pain in the MT compared to the UC
group (64% vs. 33.3% respectively).
Adherence & acceptability At post-treatment follow-
up, two participants did not complete the study, an attri-
tion rate of 8%. In the MT group, one participant did
not attend their second treatment session and was then
Table 3 Baseline characteristics. Values are means (SD) unless
stated otherwise
Characteristics MT group (n = 14) UC group (n = 12)
Age (years) 29.1 (6.3) 29.3 (5.5)
No (%) of females 7 (50%) 8 (66.7)
Body Mass Index (kg/m2) 25.9 (4.8) 27.7 (7.9)
Median (interquartile range)
duration of knee pain (months)
30 (16.5–75.25) 33 (10.5–54)
Physical activity (hours/week) 3.1 (2.6) 3.9 (3.7)
No (%) with bilateral knee pain 9 (64.3) 4 (33.3)
Anterior Knee Pain Scale 74.6 (9.9) 74.75 (12.3)
Worst pain 4.7 (1.68) 5.4 (2.3)
Average pain 3.0 (1.4) 3.9 (2.2)
No of participants who had
received previous treatment (%)
10 (71.4) 9 (75.0)
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able to complete the post-treatment analysis due to work
commitments. Table 4 illustrates that of the MT group,
five participants reported a 100% adherence to treatment
with an overall average adherence to treatment of 94%.
Treatment sessions required rearranging on seven occa-
sions; three times for illness, three times for work com-
mitments and once for childcare. This shows an
adherence to appointment rate of 92%. Adherence to
treatment and appointments was not relevant to in the
UC group.Table 4 Adherence to treatment for MT group
Participant Week 1 (%) Week 2%) Week 3 (%) W
1 100 100 100 1
2 100 100 100 1
3 100 100 100 1
4 100 100 100 1
5 100 100 100 1
6 100 100 66.66 3
7 100 100 100 1
8 66.66 100 100 1
9 100 100 100 6
10 100 100 100 6
11 66.66 100 100 1
12 100 100 100 1
13a - - - -
14 100 100 88.88 1
Weekly adherence % 94.87 100 96.58 9
aPatient 13 did not attend after the first sessionOutcome measures All questionnaires were completed
fully without any missing data yielding a missing data in-
dicator of 0%.
Treatment efficacy Based on the GROC, overall the MT
group demonstrated a larger improvement compared to
UC group (61.54% vs. 9.09% respectively). The MT group
demonstrated a greater improvement in AKP score com-
pared to UC group (Mean Difference (MD) -6.41, 95% CI:
14.23, 1.41) with a medium effect size (d = 0.70) (see
Table 5). Both worst pain NRS (−0.41; 95% CI: -1.93,
1.12) and average pain NRS (−0.02, 95% CI: -1.01.
Resources & Study Management The 9% of appoint-
ments that needed rescheduling required time to make
these changes. No safety issues were reported.
Mechanistic outcomes
The results from the mechanistic outcomes are shown
in Table 6. Evaluation of the peak torque measures
showed that both MT and UC groups showed an
increase in peak hip abductor torque from baseline to
follow up but no evidence of a systematic effect between
groups was observed (−0.63 Nm; 95% CI: -13.35, 12.09).
In terms of peak knee extensor torque, the UC group
showed a much larger increase yielding a MD of
7.96 Nm (95% CI -2.88, 18.79; d = 0.624).
The between-group comparisons of the kinematics
showed that the MT group had a reduction in peak
IR whereas the UC had a slight increase (1.70°; 95%
CI: −2.56, 5.97) yielding a small effect size (d = −0.34).eek 4 (%) Week 5 (%) Week 6 (%) Participant adherence %
00 100 100 100
00 100 100 100
00 100 100 100
00 66.66 33.33 83.33
00 100 100 100
3.33 100 66.66 77.77
00 100 100 100
00 100 100 94.44
6.66 33.33 100 83.33
6.66 100 100 94.44
00 100 100 94.44
00 66.66 100 94.44
- - -
00 100 100 98.15
6.58 89.74 92.31 93.87
Table 5 Clinical outcomes. Mean (SD) unless otherwise stated
Outcome Group Baseline (SD) Post treatment (SD) Mean difference
(baseline –post) (SD)
Confidence intervals
(95%)
Mean difference
(MT-Control)
(95% CI)
ES (d) (MT- control)
AKPS MT 75.08 (10.09) 80.31 (8.66) −5.23 (10.17) −11.37, 0.91 −6.41 (−14.23, 1.41) 0.70
UC 73.64 (12.23) 72.45 (16.94) 1.18 (7.91) −4.13, 6.49
Worst NRS MT 4.85 (1.68) 4.62 (2.10) 0.23 (2.05) −1.01, 1.47 −0.41 (−1.93, 1.12) 0.23
UC 5.27 (2.33) 4.64 (2.16) 0.64 (1.43) −0.33, 1.59
Average NRS MT 3.08 (1.38) 2.46 (1.33) 0.62 (1.33) −0.19, 1.42 −0.02 (−1.01, 0.96) 0.02
UC 3.73 (2.19) 3.09 (1.87) 0.64 (0.92) 0.02, 2.28
GROC MT 61.5% (8/13)
UC 9.1% (1/11)
AKP anterior knee pain scale, MT matched treatment, UC usual care group, NRS numerical rating scale, GROC global rating of change scale, ES effect size
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ADD (−0.17° vs. -0.04° respectively). Coronal ROM
showed that the MT group had a reduction whereas the
UC group showed a slight increase (1.12°; 95% CI: −0.72,
3.06) yielding a medium effect size (d = −0.53). Transverse
ROM showed an increase in both the MT and UC groups
(−0.32° vs. -0.78° respectively.
The within-group comparisons of the kinematic out-
comes are presented in Fig. 3. The MT intervention led
to a reduction in peak IR of 13.1% of the total transverse
ROM. There was a small reduction in coronal ROM
(4.8%) whilst peak ADD and transverse ROM demon-
strated a small increase. The UC group demonstrated an
increase for all kinematic variables.
Discussion
The aims of this study were: i) to determine the fea-
sibility of treatment matched to the specific characteris-
tics of selected PFP sub group and ii) to explore the
proposed mechanism of effect of employing strengthening
in a subgroup with baseline hip weakness. A definitiveTable 6 Mechanistic outcomes. Mean (SD) unless otherwise stated
Outcome Group Baseline (SD) Post Rx (SD) Mean d
(baselin
Hip abductor strength (Nm) MT 91.02 (28.45) 99.40 (27.89) 8.39 (15
UC 81.82 (31.76) 89.57 (33.43) 7.76 (14
Knee extensor strength (Nm) MT 91.44 (28.21) 93.12 (27.19) 1.677 (1
UC 94.32 (44.10) 103.95 (46.09) 9.64 (10
Peak Hip Adduction (°) MT 5.74 (2.70) 5.92 (2.79) −0.17 (2
UC 3.70 (3.68) 3.74 (4.99) −0.04 (4
Peak Hip Internal Rotation (°) MT −4.49 (3.26) −5.95 (5.26) 1.45 (4.9
UC −6.11 (4.82) −5.86 (7.22) −0.25 (5
Total coronal hip ROM (°) MT 9.77 (3.62) 9.29 (2.60) 0.47 (2.1
UC 10.04 (4.69) 10.74 (4.79) −0.70 (2
Total transverse hip ROM (°) MT 11.08 (2.65) 11.39 (2.08) −0.32 (2
UC 9.12 (5.76) 9.90 (5.02) −0.78 (1
MT matched treatment, UC usual care group, ROM range of movement, ES effrandomised controlled trial (RCT) appears achievable in
terms of adherence, attrition, eligibility and outcome data.
Some consideration is required to develop strategies to
enhance the ability to quantify clinical differences between
groups. In terms of the potential mechanism of effect for
hip strengthening, an improvement was shown for peak
IR following MT.
Feasibility outcomes
Based on our eligibility thresholds for selecting a ‘weak’
hip group, we predetermined that for feasibility;
eligibility should reach or exceed 32%. Our observed
eligibility rate of 37% provides reassurance. It is also
expected that other people with PFP, ineligible for the
current study based on hip strength, may well classify
into other subgroups as shown in recent studies [29].
This eligibility rate for hip weakness is less than the 88%
(at 1SD) reported by Selfe et al. (2016) [29] but may be
explained by the current study measuring an isokinetic
contraction rather than an isometric contraction and as a
consequence the different strength thresholds applied.ifference
e-post) (SD)
Confidence intervals
(95%)
Mean difference
(MT-UC) (95% CI)
ES (d) (MT - UC)
.28) −17.62, 0.85 −0.63 (−13.35, 12.09) −0.04
.59) −17.56, 2.05
4.57) −10.48, 7.12 7.96 (−2.88,18.79) 0.62
.15) −16.46, − 2.82
.84) −1.89, 1.54 −0.14 (−3.12, 2.85) 0.04
.18) −2.84, 2.77
8) −1.56, 4.46 1.70 (−2.56, 5.97) −0.34
.06) −3.65, 3.15
9) −0.86, 1.79 1.12 (−0.72, 3.06) −0.53
.27) −2.23, 0.82
.49) −1.83, 1.19 0.46 (−1.45, 2.38) −0.20
.93) −2.08, 0.52
ect size
Fig. 3 Percentage change of total ROM in kinematic outcomes
between baseline and post intervention
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multicentre RCTs would need to ensure cross-site calibra-
tion of the isokinetic systems and site visits to monitor
fidelity of the testing procedures and the intervention.
Recent studies have reported that a greater adherence
to treatment is associated with increased probability of
better outcomes [2]. An adherence to treatment and
adherence to appointments over 90% is promising.
Approximately 30% (4/13) achieved complete adherence
to all treatment sessions and 9% of appointments re-
quired rearranging. Our adherence rate is comparable to
a larger RCT [18] who found a 80.3% adherence rate for
a 6 week hip strengthening in PFP. It’s anticipated that
rearranging appointments for participants would be
more challenging for a larger sample over multiple sites.
Consequently, strategies to enhance adherence with the
use of activity monitoring technology and reminder ser-
vices need to be considered [56].
No differences between groups were found for either
the average or worst NRS values. This might be explained
by the difference in almost a score of one in average base-
line NRS, a feature that would likely be minimised in a lar-
ger full-scale trial. Previous RCTs [18, 57] have also used
eligibility criteria requiring a minimum NRS score of three
out of 10 pain score. Setting a minimum pain score as part
of the inclusion criteria is suggested for a future RCT.
The difference between groups for the AKP score did
not reach the predetermined minimal clinically import-
ant difference (MCID) of eight points [58], although
there was a trend towards a meaningful benefit. These
findings are similar to the only other RCT to have strati-
fied a PFP cohort, used in a study of a foot orthoticintervention over 6 weeks. Mills et al. (2011) [12] se-
lected their participants based on predictors shown to
predict success with orthotics, which included age,
height, baseline pain severity and a static foot measure.
They also found a significant difference between groups
in terms of GROC with no differences in AKP score or
VAS pain. They suggest that GROC is able to capture
the multidimensional nature of PFP (characterised by
pain, disability and functional limitation) compared to
AKP score and VAS pain which are more one dimen-
sional [12].
Mechanistic outcomes
Stratifying for hip abductor weakness led to a reduction
of approximately 13% for peak IR in the MT group
following strengthening treatment. This is important
considering that an increase peak IR has been associated
with PFP during stair descent [59, 60]. This reduction in
peak IR occurred with a slight worsening of their trans-
verse ROM suggesting that following treatment, people
in the MT group were initiating stance phase in a more
desirable externally rotated hip position. A reduction in
peak IR and a slight increase in peak ADD are perhaps
surprising considering that participants were stratified
for hip abductor weakness. However, recent strength
measures conducted on 501 healthy athletes [61] have
shown that hip abductor and hip external rotation
strength are highly correlated (r = 0.66) indicating this
subgroup were likely to have also demonstrated weak-
ness into both hip abduction and external rotation.
Hip strength increased in both groups by a similar
difference, which is likely the result of over a third of
participants in the UC group being engaged in physio-
therapy. Post-hoc analysis of those participants in the
UC group who received no treatment show an increase
of only 3.9 Nm in hip abductor strength (results not
shown). In the MT group the change in hip strength was
9%, which is a comparable improvement to previous hip
strengthening programmes over a similar training dur-
ation [21, 27]. The increase in strength for both groups
but with only kinematic improvements seen in the MT
group might suggest that strength, on its own, cannot
explain the improvement seen in peak IR. Direct
comparison with previous studies [17, 26–28] remains
difficult due to the differences in assessment tasks (e.g.
running, stairs etc.) and the specific kinematic outcomes
(e.g. peak, average angles etc.) investigated. Previous
studies [27, 28] that have observed the effect of hip
strengthening on running kinematics in people with PFP
found no change in kinematics despite increases in hip
abductor strength. Only Baldon et al. (2014) [17] re-
ported changes in kinematics, during a single leg squat,
following a hip strengthening programme. Yet, this
training programme, did include constant feedback on
Drew et al. BMC Musculoskeletal Disorders  (2017) 18:338 Page 9 of 11lower limb alignment which suggests a more movement
retraining approach [62] rather than pure strength train-
ing. It remains possible that the improvements observed
in peak IR in the current study was the result of using
progressive loading within a tailored treatment regime
and selecting participants who were most likely to bene-
fit from strengthening.Limitations
This feasibility study presents with several limitations.
Firstly, the study was performed in a single centre. Future
RCTs would be required to be multicentre to improve
generalisability, which is anticipated to introduce new
feasibility issues. The findings of the current study would,
however, inform the documentation of standard operating
procedures in terms of recruitment; data collection and
intervention provision to ensure any future study could be
operationalised across different geographical locations.
Secondly, the current study did not blind assessors to
group allocation, which could lead to potential bias [63].
Every effort was made for participants to complete
PROMs in isolation and objective biomechanical out-
comes were acquired in accordance with strict protocols
with little chance of introducing bias. Future RCTs should
make every effort to introduce outcome assessor blinding
and consider measuring the level of this outcome assessor
blinding [64] Thirdly, the use of a UC group was intended
to represent the heterogeneity of management available in
real, daily practice and thus improve the external validity
[65]. For the purposes of exploring the mechanism of hip
strengthening, however, the fact that over half of the UC
group received physiotherapy input potentially dilutes the
between-group findings. Comparison with a control group
receiving no active intervention would remedy this issue.Conclusion
The potential benefits associated with stratification and
subgrouping within PFP have been advocated since the
first International Patellofemoral Pain Retreat Consensus
statement [10]. This study suggests that targeted treat-
ment provides a greater improvement in overall function
and self-reported improvement in comparison to usual
care. Additionally, the improvements seen in peak IR fol-
lowing MT suggest this may be a plausible mechanism of
effect for hip strengthening when treatment is matched to
an appropriate subgroup. Strategies to enhance the ability
to detect clinical difference should be considered and
might be improved by selection of participants with a
minimum pain score. Ultimately, a pragmatic, multicentre
RCT with a sufficiently powered cohort appears achiev-
able and should be conducted to determine the clinical
and cost-effectiveness of a stratified treatment approach
versus usual care for people with PFP.Additional files
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